GRIFOLS

Grifols, S.A.
Avinguda de la Generalitat 152-158
08174 Sant Cugat del Vallès
Barcelona - ESPAÑA
Tel. [34] 935 710 500
Fax [34] 935 710 267
www.grifols.com

Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("**Grifols**") hereby informs about the following

RELEVANT EVENT

The U.S. Food and Drug Administration ("**FDA**") has approved Grifols' new 20% subcutaneous immunoglobulin product, Xembify®, which is used to treat primary immunodeficiencies.

The FDA approval of Xembify® marks the culmination of an important R+D+i project for Grifols, as well as a step forward in its long-term sustainable growth strategy, and it reinforces Grifols' commitment to patients and healthcare professionals by expanding its product portfolio to better serve individuals with primary immunodeficiences. Grifols is currently a market leader in the production and marketing of immunoglobuline, with 30.3%[1] market share (in volume) in the United States.

The company plans to launch Xembify® in the United States during the last quarter of 2019, and it is working with healthcare authorities to obtain approval in Canada, Europe, and other markets.

In Barcelona, on 4 July 2019

Nuria Martín Barnés
Secretary to the Board of Directors

[1] Source: Grifols Global Plasma Database, provisional data 2018